Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes
Patients developing low blood cell counts during imetelstat treatment for bone marrow disease showed better responses, helping doctors interpret treatment progress.
This analysis of the IMerge Phase 3 trial found that patients who developed cytopenias during imetelstat treatment for lower-risk MDS had better clinical responses. The findings suggest cytopenias may indicate on-target drug activity and help guide treatment expectations.
What the study was
- Study design
- Post-hoc analysis of Phase 3 RCT
- Population
- Lower-risk MDS patients from IMerge Phase 3 trial
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Blood Cancer Journal
Why it surfaced
Clinically actionable insight from a Phase 3 MDS trial linking side effects to efficacy; relevant for hematology practice.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.